Teleflex has completed the previously announced acquisition of US-based medical equipment manufacturer NeoTract for approximately $1.1bn.

As part of the deal, Teleflex bought NeoTract for an upfront cash payment of $725m at closing, and up to an additional $375m after the achievement of select commercial milestones associated with sales until the end of 2020.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Teleflex will have access to NeoTract’s FDA-cleared UroLift System, a minimally invasive technology developed to treat lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH).

Through a transurethral outpatient procedure, UroLift delivers permanent implants to hold open the urethra and to minimise prostate obstruction without cutting, heating or removing the prostate tissue.

Teleflex offers solutions in the fields of vascular and interventional access, surgical, anaesthesia, cardiac care, urology, emergency medicine, and respiratory care.

“The addition of NeoTract is expected to improve Teleflex’s presence in the urological market.”

The Teleflex family consists of Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, and Weck brands.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The addition of NeoTract is expected to improve Teleflex’s presence in the urological market as UroLift is used to address a significant medical issue and targets a total addressable $39bn market.

Since receipt of CE-Mark in 2010 and de novo 510(k) in 2013, UroLift has been the subject of a significant number of studies, including two randomised clinical trials, seven open-label studies, and three meta-analyses.

The system also has broad, sustainable reimbursement in place, including dedicated category 1 CPT codes specific to the UroLift System procedure and is 100% covered by Medicare Administrative Contractors, which translates to approximately 174 million lives in the US.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact